A Study of SRSD384 in Overweight or Obese Participants

NCT07557355 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing the safety of SRSD384 in adults who are overweight or obese by monitoring side effects that may occur during the study.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 78 people Planned (estimated).

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2026-06 · est. completion 2027-10

What this study is testing ClinicalTrials.gov NCT07557355 ↗

Description as written by the study sponsor.

This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD384 alone in overweight or obese participants (Part A) and in combination with tirzepatide in overweight or obese participants with T2DM (Part B).

Treatments tested

SRSD384 injection Drug

Administered S.C. per the protocol
Placebo Drug

Administered S.C. per the protocol

Main thing measured	Incidence of treatment-emergent adverse events (TEAEs)
Sponsor	Sirius Therapeutics Co., Ltd.
Conditions studied	Overweight , Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07557355 ↗